AstraZeneca is joining Bristol Myers Squibb in the emerging autoimmune cell therapy space, paying Quell Therapeutics $85 million upfront to collaborate on candidates including a “one and done” cure for Type 1 diabetes. Internally, Quell is validating its technology with a candidate, QEL-001, designed to stop organ rejection and end the need for lifelong immunosuppression, but the model has broader applications. Source: Fierce Biotech 9/6/2023